<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Remimazolam</id>
	<title>Remimazolam - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Remimazolam"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Remimazolam&amp;action=history"/>
	<updated>2026-04-25T19:31:18Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Remimazolam&amp;diff=2393097&amp;oldid=prev</id>
		<title>Deepika vegiraju: Created page with &quot;== &#039;&#039;&#039;What  is remimazolam?&#039;&#039;&#039; == Remimazolam (BYFAVO) for injection is a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults u...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Remimazolam&amp;diff=2393097&amp;oldid=prev"/>
		<updated>2021-07-05T17:06:29Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;== &amp;#039;&amp;#039;&amp;#039;What  is remimazolam?&amp;#039;&amp;#039;&amp;#039; == Remimazolam (BYFAVO) for injection is a &lt;a href=&quot;/wiki/Benzodiazepine&quot; title=&quot;Benzodiazepine&quot;&gt;benzodiazepine&lt;/a&gt; indicated for the induction and maintenance of procedural &lt;a href=&quot;/wiki/Sedation&quot; title=&quot;Sedation&quot;&gt;sedation&lt;/a&gt; in adults u...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== &amp;#039;&amp;#039;&amp;#039;What  is remimazolam?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
Remimazolam (BYFAVO) for injection is a [[benzodiazepine]] indicated for the induction and maintenance of procedural [[sedation]] in adults undergoing procedures lasting 30 minutes or less.&lt;br /&gt;
&lt;br /&gt;
[[File:Remimazolam.svg|thumb]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;youtube&amp;gt;&lt;br /&gt;
title=&amp;#039;&amp;#039;&amp;#039;{{PAGENAME}}&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
movie_url=http://www.youtube.com/v/=1Sdza-NmSM4&lt;br /&gt;
embed_source_url=http://www.youtube.com/v/=1Sdza-NmSM4&lt;br /&gt;
&amp;amp;rel=1&lt;br /&gt;
wrap = yes&lt;br /&gt;
width=750&lt;br /&gt;
height=600&lt;br /&gt;
&amp;lt;/youtube&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the uses of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* This medicine is indicated for the induction and maintenance of procedural [[sedation]] in adults undergoing procedures &amp;#039;&amp;#039;&amp;#039;lasting 30 minutes or less&amp;#039;&amp;#039;&amp;#039;.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How does this medicine work?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* BYFAVO is a [[benzodiazepine]]. &lt;br /&gt;
* BYFAVO &amp;#039;&amp;#039;&amp;#039;binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABAA] receptors)&amp;#039;&amp;#039;&amp;#039;, while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. &lt;br /&gt;
* BYFAVO, like other benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Who Should Not Use this medicine ?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine cannot be used in patients with:&lt;br /&gt;
* In patients with a history of severe [[hypersensitivity]] reaction to dextran 40 or products containing dextran 40.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What drug interactions can this medicine cause?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine cannot be co administered with CNS depressant medications, including [[opioid analgesics]], other [[benzodiazepines]], and [[propofol]]. Continuously monitor vital signs during sedation and through the recovery period. &lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Is this medicine FDA approved?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* It was approved for use in the United States in 2020.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How should this medicine be used?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Each single-patient-use vial contains 20 mg BYFAVO [[lyophilized]] powder for [[reconstitution]]. &lt;br /&gt;
* The product must be prepared immediately before use.&lt;br /&gt;
* To reconstitute, add 8.2 mL sterile 0.9% Sodium Chloride Injection, USP, to the vial, directing the stream of solution toward the wall of the vial. &lt;br /&gt;
* Gently swirl the vial (do not shake) until the contents are fully dissolved. &lt;br /&gt;
* The reconstituted product will deliver a final concentration of 2.5 mg/mL solution of BYFAVO.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Adult Patients:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Administer an initial dose intravenously as a 5 mg push injection over a 1-minute time period.&lt;br /&gt;
* If necessary, administer supplemental doses of 2.5 mg intravenously over a 15-second time period. &lt;br /&gt;
* At least 2 minutes must elapse prior to the administration of any supplemental dose.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;ASA III-IV Patients:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Based on the general condition of the patient, administer 2.5 mg to 5 mg over 1-minute time period.&lt;br /&gt;
* If necessary, administer supplemental doses of 1.25 mg to 2.5 mg intravenously over a 15-second time period. &lt;br /&gt;
* At least 2 minutes must elapse prior to the administration of any supplemental dose. &lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the  dosage forms and brand names of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing doasage form:&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;As single-patient-use vial:&amp;#039;&amp;#039;&amp;#039; Each glass, single-patient-use vial of BYFAVO (remimazolam) for injection contains 20 mg remimazolam.&lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing brand namesː&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;BYFAVO&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;What side effects can this medication cause?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
Common possible side effects  of this medicine include:&lt;br /&gt;
* hypotension&lt;br /&gt;
* hypertension&lt;br /&gt;
* diastolic hypertension&lt;br /&gt;
* systolic hypertension&lt;br /&gt;
* hypoxia&lt;br /&gt;
* diastolic hypotension&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039; What special precautions should I follow?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Hypersensitivity reactions including [[anaphylaxis]] may occur.&lt;br /&gt;
* [[Benzodiazepine]] use during pregnancy can result in neonatal sedation. &lt;br /&gt;
* Observe newborns for signs of sedation and manage accordingly. &lt;br /&gt;
* Weigh benefits against potential risks when considering elective procedures in children under 3 years old.&lt;br /&gt;
* since this medicine may cause pediatric Neurotoxicity.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What to do in case of emergency/overdose?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
Overdose of this medicine  may lead to [[CNS depression]], associated with drowsiness, confusion, and lethargy, with possible progression to [[ataxia]], [[respiratory depression]], and [[hypotension]].&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Management for overdosage:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* [[Flumazenil]] is indicated for the reversal of the [[sedative]] effects of [[benzodiazepines]] and may be used in situations when an overdose with BYFAVO is known or suspected. &lt;br /&gt;
* Flumazenil will only reverse benzodiazepine-induced effects and will not reverse the effects of other medications, such as [[opioid]] [[analgesics]]. &lt;br /&gt;
* Monitor patients treated with flumazenil for re-sedation, [[respiratory depression]], and other residual benzodiazepine effects. &lt;br /&gt;
* Re-sedation by BYFAVO has not been observed after administration of flumazenil in clinical trials.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Can this medicine be used in pregnancy?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Infants born to mothers using benzodiazepines during the later stages of pregnancy have been reported to experience symptoms of sedation.&lt;br /&gt;
* Benzodiazepines cross the placenta and may produce [[respiratory depression]] and [[sedation]] in neonates.&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;Can this medicine be used in children?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
* Safety and effectiveness in pediatric patients have not been established. &lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What should I know about storage and disposal of this medication?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Store at controlled room temperature 20°C to 25°C (68°F to 77°F) excursions between 15° and 30°C (59° and 86°F) are allowed.&lt;br /&gt;
* Reconstituted BYFAVO can be stored in the vial for up to 8 hours under controlled room temperature at 20°C to 25°C (68°F to 77°F).&lt;br /&gt;
* Protect vials from light once they are removed from packaging.&lt;br /&gt;
* Discard unused portion.&lt;br /&gt;
&lt;br /&gt;
{{Benzodiazepines}}&lt;br /&gt;
{{GABAAR PAMs}}&lt;br /&gt;
{{Portal bar|Medicine}}&lt;br /&gt;
&lt;br /&gt;
[[Category:GABAA receptor positive allosteric modulators]]&lt;br /&gt;
[[Category:Imidazobenzodiazepines]]&lt;br /&gt;
[[Category:Pyridines]]&lt;br /&gt;
[[Category:Bromoarenes]]&lt;br /&gt;
[[Category:Methyl esters]]&lt;br /&gt;
{{coststubd}}&lt;/div&gt;</summary>
		<author><name>Deepika vegiraju</name></author>
	</entry>
</feed>